Table 3

Baseline variables associated with HBeAg seroconversion in Peg-IFN and NUC cohorts

Factors	Univariate			Multivariate
	OR	95% CI	p Value	OR	95% CI	p Value
Peg-IFN cohort
Age	0.932	0.354 to 2.456	0.887
Gender	1.223	0.643 to 2.327	0.540
Genotype	1.403	0.816 to 2.413	0.220
Baseline ALT level	2.132	1.030 to 4.416	0.041	2.378	1.096 to 5.159	0.028
Baseline HBV DNA level	2.622	1.486 to 4.626	0.001	2.448	1.344 to 4.458	0.003
Baseline HBsAg level	2.320	1.362 to 3.952	0.002
Baseline HBeAg level	2.435	1.363 to 4.350	0.003
Baseline Anti-HBc level	3.077	1.790 to 5.289	<0.001	2.658	1.519 to 4.651	0.001
NUC cohort
Age	1.924	1.050 to 3.527	0.034	1.964	1.061 to 3.636	0.032
Gender	1.637	1.029 to 2.603	0.037
Genotype	1.137	0.768 to 1.682	0.522
Baseline ALT level	1.514	0.901 to 2.545	0.118
Baseline HBV DNA level	1.930	1.267 to 2.939	0.002	1.762	1.148 to 2.706	0.010
Baseline HBsAg level	1.737	1.170 to 2.579	0.006
Baseline HBeAg level	1.251	0.846 to 1.851	0.262
Baseline Anti-HBc level	2.110	1.424 to 3.126	<0.001	1.994	1.336 to 2.975	0.001
Overall
Treatment strategy	2.316	1.675 to 3.202	<0.001	2.237	1.598 to 3.132	<0.001
Age	1.784	1.087 to 2.927	0.022
Gender	1.487	1.025 to 2.158	0.036
Genotype	1.182	0.866 to 1.614	0.292
Baseline ALT level	1.715	1.128 to 2.609	0.012	1.707	1.100 to 2.647	0.017
Baseline HBV DNA level	2.123	1.521 to 2.964	<0.001	1.964	1.387 to 2.781	<0.001
Baseline HBsAg level	2.066	1.514 to 2.820	<0.001
Baseline HBeAg level	1.648	1.199 to 2.267	0.002
Baseline Anti-HBc level	2.509	1.836 to 3.428	<0.001	2.178	1.577 to 3.009	<0.001

The variables enrolled in logistic regression analysis were age (≤40 vs >40 years), gender (female vs male), genotype (non-C vs C), baseline ALT level (≥2 vs <2 ULN), baseline HBV DNA level (<9 vs ≥9 log₁₀ copies/mL), baseline HBsAg level (<4 vs ≥4 log₁₀ IU/mL), baseline HBeAg level (<3 vs ≥3 log₁₀ PEIU/mL), baseline anti-HBc level (≥4.4 vs <4.4 log₁₀ IU/mL) and treatment strategy (Peg-IFN vs NUC).
ALT, alanine aminotransferase; anti-HBc, hepatitis B core antibody; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; NUC, nucleos(t)ide analogue; Peg-IFN, peginterferon; ULN, upper limit of normal.